⌘K
t
Kanabo Group PLC announced that 1,080,247 ordinary shares, issued to advisers and service providers, were admitted to the Standard List of the London Stock Exchange on 26 May 2023. Following this admission, Kanabo's total voting rights comprise 500,385,193 ordinary shares of 2.5p each in issue, a figure shareholders should use for disclosure calculations.
| Date | 26 May 2023 |
| Time | 10:30:01 |
| Category | Capital structure |
| ID | 8255A |
26 May 2023
Kanabo Group PLC
("Kanabo" or the "Company")
Total Voting Rights
Following the Company's announcement on 23 May 2023, the Company is pleased to announce that 1,080,247 ordinary shares issued to advisers and service providers have been admitted today, 26 May 2023, to the Standard List of the London Stock Exchange ("Admission").
Following Admission, for the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, Kanabo announces that it has 500,385,193 ordinary shares of 2.5p each in issue ("Ordinary Shares"), each share carrying the right to one vote. The figure of 500,385,193 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please visit http://www.kanabogroup.com/ or contact the following:
Enquiries:
|
Kanabo Group plc Avihu Tamir, Chief Executive Officer Assaf Vardimon, Chief Financial Officer
|
via Vigo Consulting +44 (0)20 7390 0230 |
|
Peterhouse Capital Ltd (Financial Adviser and Broker) Eran Zucker/ Lucy Williams / Charles Goodfellow
|
+44 (0)20 7469 0930 |
|
Vigo Consulting (Financial Public Relations/Investor Relations) Jeremy Garcia / Fiona Hetherington / Verity Snow |
+44 (0)20 7390 0230
|
About Kanabo Group Plc
Kanabo Group Plc (LSE:KNB) is a healthtech company committed to revolutionising patient care through its innovative technology platform and disruptive product offerings. Since its inception in 2017, Kanabo has been focused on researching, developing, and commercialising regulated medicinal cannabis-derived formulations and therapeutic inhalation devices.
Kanabo's NHS-approved online telehealth platform, The GP Service, provides patients with video consultations, online prescriptions, and primary care services. The Company is a leader in its field, focusing on improving patient outcomes and providing more accessible healthcare experiences.
In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under the expert guidance of its technological and product expertise. Treat It initially focuses on chronic pain management using plant-based medicine and treatments that are currently unavailable through traditional channels.
At Kanabo Group Plc, we are dedicated to providing patients with the highest quality medical treatments and more accessible healthcare experiences.
Visit www.kanabogroup.com for more information.